Introduction {#Sec1}
============

Bone transplants are broadly used in the treatment of open fractures, especially for providing mechanical or structural support and promoting the bone tissue formation \[[@CR1], [@CR2]\]. Due to high rate of bone infections and infection-related complications in open fractures, it is necessary to load bone implants with antibiotics for treating osteomyelitis or eradicating, reducing or preventing contaminations \[[@CR3]\]. In addition, the synthetic bone material must be safe and suitable for implantation in vivo. Calcium sulfate has got a long clinical history as bone biomaterial because apart from providing structural support, it holds good biocompatibility, osteoinductivity and bioabsorbability and can serve as a vehicle for delivery and local release of antibiotics \[[@CR4]--[@CR8]\]. For instance, Kelly et al. (2001) successfully used surgical grade calcium sulfate pellets as convenient and safe bone graft substitute for the treatment of patients with bone defects \[[@CR9]\]. Additional studies on bone graft substitutes have equally confirmed the biocompatibility of calcium sulfate composites and suggested their use as suitable bone implant material for in vivo therapies \[[@CR10], [@CR11]\]. In our previous work, we used calcium sulfate particles impregnated with vancomycin for the treatment of infected bone defects of 28 cases of open fractures among which 26 cases were followed up, and found that this material is beneficial for osteoblasts migration and vascular ingrowth and can successfully promote the fracture healing \[[@CR12]\]. However, we recorded some shortcomings, such as low drug delivery and drug release ability and the difficulty to achieve the maintenance of drug concentration. Therefore, a drug delivery material, which can sustain drug release, is needed for the clinical treatment.

In the recent years, the use of mesoporous silica nanoparticles (MSNs) has been extended in biomedical fields such as cancer therapy, drug and gene delivery, biosensors, and enzyme immobilization \[[@CR13]\]. MSNs can be used as drug carriers, can sustain delivery and local release of drugs and has good biocompatibility. For example, Kempen et al. \[[@CR8]\] showed that mesenchymal stem cells (MSCs) labeled with MSN had no cytotoxicity at the 250 µg/mL concentration required for labeling. It was also reported that multi-functional MSNs coated with poly (N-isopropylacrylamide) (PNIPAM) composite nanomaterials can easily carry guest molecules into human breast carcinoma cells (MCF-7) and display minute cytotoxicity to the cells \[[@CR14]\]. Previously, a biocompatible silica-based nanoparticles synthesized by incorporating the bone-forming peptide (BFP) into MSNs showed better cell proliferation and osteogenic differentiation and could be used as a bioactive material for bone repairing, bone regeneration, and bio-implant coating applications \[[@CR15]\]. Most of drugs are loaded into the pores of MSN and can only be released by diffusion. This significantly reduces and retards the local drug release and subsequently improves drug bioavailability. However, MSN itself is in a powder state, which makes it difficult to be directly used as bone implant material. Up to now, studies have shown that by using MSNs loading rate of 5 %, artificial bone materials with a relatively good solidity can be obtained \[[@CR11], [@CR16]\]. Therefore, by combining MSNs and calcium sulfate, a new type of robust artificial bone material for bone repair with sustained release effect can be obtained. However, to potentiate this material for suitable use in the human body, it is primarily necessary to investigate its impacts on the organisms.

Therefore, in the present study, we aimed to examine the biocompatibility of the previously synthesized artificial bone based on vancomycin loaded mesoporous silica nanoparticle and calcium sulfate composites \[[@CR17]\] in order to provide experimental basis for its application as a bone graft materials.
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### Materials {#Sec4}

The cells of murine osteoblast MC3T3-E1 were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Penicillin, streptomycin, fetal bovine serum (FBS) and α-MEM medium were all purchased from Hyclone (Logan, UT). The artificial bone based on vancomycin loaded MSNs and calcium sulfate composites was obtained from the Key Laboratory of Molecular Engineering of Polymers of Fudan University. The medical grade calcium sulfate was purchased from Tianjin Sheehan biochemical technology co., LTD. Cholecystokinin octapeptide (CCK-8) was purchased from Peptide Institute (Minoh, Japan) while alkaline phosphatase (ALP) detection kit was provided by Nanjing Jiancheng Bioengineering Institute.

### Preparation of leaching solutions {#Sec5}

Bone cement based on vancomycin loaded MSNs and calcium sulfate composites (5 %Van-MSN-CaSO~4~) \[[@CR11]\] and calcium sulfate impregnated with vancomycin (Van-CaSO~4~) bone implant \[[@CR12]\] were prepared as described elsewhere \[[@CR11], [@CR12]\]. A certain amount of prepared Van-MSN-CaSO~4~ or Van-CaSO~4~ was sterilized under ultraviolet radiation, soaked in α-MEM medium supplemented with 10 % FBS at a soaking rate of 0.1 g/ml according to ISO10993.5 standards and incubated hermetically at 37 °C for 72 h. Subsequently, the obtained leaching solutions were filtered and stored at 4 °C until use.

### Cell cultivation, cytotoxicity evaluation and alkaline phosphatase activity {#Sec6}

MC3T3-E1 cells were cultured in α-MEM culture medium supplemented with 10 % (v/v) FBS (Hyclone, USA). Incubation was performed in a CO~2~ incubator (5 % CO~2~, 95 % air). The cells were subcultured every 2 or 3 days.

To evaluate the cytotoxicity of artificial bone composites, third-generation MC3T3-E1 cells were seeded in 96-well plates (4000 cells/well containing 100 µl of α-MEM medium in 5 % CO~2~ controlled air incubator at 37 °C for 24 h to allow cell attachment. After cell adhesion on the bottom of the wells, the culture medium was aspirated and changed into fresh medium supplemented with dilutions of the leaching solutions (100, 50 and 25 % concentrations of filtrated leaching solutions) prepared as indicated in Table [1](#Tab1){ref-type="table"}. Six wells were seeded for each dilution and the negative control for which no leaching solution was added. After 1, 2, 3 and 5 days cultivation, cells were washed twice with fresh α-MEM medium and replaced by 100 µl of the same medium plus 10 µl of CCK-8. After further cultivation for 2 h, we measured the absorbance at 450 nm using the ELISA plate reader according to the guidelines of CCK8 assay kit.Table 1Experimental groups and interventionsExperimental groupImplementation planA (100 %Van-MSN-CaSO~4~ original leaching solution)3 ml Van-MSN-CaSO~4~ original solutionB (50 %Van-MSN-CaSO~4~ dilution)1.5 ml A + 1.5 ml α-MEM medium supplemented with 10 % FBSC (25 % Van-MSN-CaSO~4~ dilution)0.5 ml A + 1.5 ml α-MEM medium supplemented with 10 % FBSD (100 %Van-CaSO~4~ original leaching solution)3 ml Van-CaSO~4~ original solutionE (50 %Van-CaSO~4~ dilution)1.5 ml D + 1.5 ml α-MEM medium supplemented with 10 % FBSF (25 %Van-CaSO~4~ dilution)0.5 ml D + 1.5 ml α-MEM medium supplemented with 10 % FBSG(negative control)3 ml α-MEM medium supplemented with 10 % FBS

For ALP assay, the cells were cultured under the same conditions as that of the CCK8 assay. After 3 and 5 days, ALP activity was measured by spectrophotometric methods at 520 nm using an ALP assay kit according to the manufacturer's protocol.
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### Animal population {#Sec8}

Twelve adult male and female New Zealand rabbits, with a mean weight of 2.5 kg and ages ranging from 4 to 5 months were divided into control group (n = 3), simple MSNs implant group (n = 3), 5 %Van-MSN-CaSO~4~ implant group (n = 3) and CaSO~4~ implant group (n = 3). All procedures were performed in accordance with standard guidelines as described in the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health 85-23, revised 1996). All animal protocols were agreed by the local Institutional Animal Care and Use Committee of Tongji University.

### Surgical procedure {#Sec9}

The surgical procedure adopted for implantation of bone materials is depicted in Fig. [1](#Fig1){ref-type="fig"}. Prior to surgical processes, general anesthesia was achieved by intravenous injections of pentobarbital at a dose of 1 ml/kg body weight whereas 2 % lidocaine was used for local anesthesia in the subcutaneous area of the insertion site. After shaving, povidone iodine disinfection and placing surgical drapes, about 3 cm longitudinal incision was achieved in the area of the distal femoral diaphysis, followed by a step by step separation to expose the lateral condyle cortical bone. Thereafter, bone defects (ø 3 mm, depth 2 mm) were created by drilling perpendicularly to the direction of the cortical bone, with cautious avoidance of the penetration in the lateral cortex. After washing the wound with physiological water, implant materials corresponding to experimental and control groups were inserted. For the blank control group the wound was simply open without implantation of bone materials. Finally, following disinfection, surgical sites were closed using resorbable sutures and rabbits woken up after caging.Fig. 1Images of the surgical procedures adopted for implantation of artificial bones. **a** Shaving and desinfection, **b** perforation to create bone defect, **c** implantation of artificial bones in created defects, **d** sutures

### Samples collection {#Sec10}

Blood samples were taken respectively at 1, 2 and 3 months after operation, centrifuged at 3000 g for 5 min for serum separation and cryopreserved at −80 °C.

For collection of bone samples and main viscera, animals were sacrificed after 12 weeks by intravenous injection of 20 ml of air. Distal femurs of rabbits containing defects and major rabbit organs (heart, liver, spleen, lung, and kidney) were harvested en bloc after operation and immersed in paraformaldehyde until further processing for histological analysis. In histological analysis of viscera, samples were collected after sacrifice of normal animals without implants or defects.

### Histological and histopathological evaluation {#Sec11}

The conventional HE staining was used for microscopic examination of paraffin embedded histological sections of main organs (5--6 microns thickness). Bone specimens were decalcified and HE stained. The decalcified sections were observed under a light microscope (Nikon Eclipse 50i) with a 10x magnification objective. Eight nonconsecutive images of each HE-stained specimen section were blindly analyzed by one expert observer. The images were digitally captured (Nikon H500S) and visualized with Image Pro-Plus 6.0 for Windows.

### Micro-CT examination {#Sec12}

The micro-CT analysis was performed on samples from the lateral femur condyle (including the defect with implant material) using the high-resolution micro-CT system Skyscan 1076 (SkyScan, Aartselaar, Belgium). The X-ray source was an air-cooled, sealed Hamamatsu 100/250 tube with a focal spot size \<8 µm. The X-ray tube was run at source voltage of 40 kV and source current of 250 µA without filter. The X-ray detector consisted of a Princeton Instruments camera with camera pixel size of 12.60 µm and camera X/Y Ratio of 1.0000. NRecon program version 1.6.9.4 was employed for reconstruction.

The quality of new bone was evaluated based on pictures analyzed by CTAn, a micro-CT analysis program. The bony tissue of the new bone was analyzed with a ROI (region of interest) at a width of 0.99 mm and a height of 2.48 mm. The bone portion containing implants (defects zone) was analyzed using an ROI at a size of 0.97 mm and a height of 2.48 mm. For quantification of the quantity and quality of the new bone, we evaluated the percent bone volume (BV/TV) and specific bone surface (BS/BV) as well as trabecular thickness (Tb·Th) and trabecular number (Tb·N).

### Statistical analysis {#Sec13}

The experimental data were expressed as mean ± standard deviation. SPSS20.0 statistical software was used for statistical analysis using one way-ANOVA for comparison between multiple samples. Multiple intra-groups comparisons were achieved through SNK test. Statistical significance was evaluated with a p-values cutoff of \<0.05.

Results {#Sec14}
=======
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### Cytotoxicity test {#Sec16}

In order to evaluate the cyto-compatibility of bone implant materials, the CCK-8 cytotoxicity assay was performed after 1, 2, 3 and 5 days cultivation of MC3T3-E1 cells with different concentrations of leaching solutions stemmed from bone implants. As displayed in Fig. [2](#Fig2){ref-type="fig"}a, an increase in absorbance from day 1 to day 7 was recorded, which indicates cell viability with both the Van-CaSO~4~ and Van-MSN-CaSO~4~ implant materials. Moreover, the proliferation behaviors of cells with different implant materials were very similar to each other in every measurement point. Indeed, comparatively to the negative control group and the Van-CaSO~4~ artificial bone control group, Van-MSN-CaSO~4~ implant material had no inhibitory effect on the proliferation of mice osteoblasts (P \> 0.01) and there was no significant difference between groups or between concentration groups (*P* \> 0.01).Fig. 2*In vitro* analysis of the biocompatibility of different artificial bone leaching solutions measured after 5 days cultivation: **a** Proliferation of MC3T3-E1 cells, **b** phosphatase alkaline (ALP) activity of MC3T3-E1 cells

### Alkaline phosphatase assay {#Sec17}

To assess the effect of bone cements on osteoblast differentiation, we determined the ALP activity of MC3T3-E cells after 3 and 5 days cultivation. The measurement of ALP activity (Fig. [2](#Fig2){ref-type="fig"}b) showed significant differences between the blank control group and the leaching solutions with dilution rates ≥50 %. Between leaching solutions with dilution rate of 25 % and the blank control, no statistically significant differences were observed. No significant differences were observed among Van-MSN-CaSO~4~ and Van-CaSO~4~ leaching solutions. Nevertheless, MC3T3-E1 cells produced increasing ALP activity with the increase of the concentrations of leaching solutions. This result indicated the osteoconductivity of both kinds of bone cements which must be attributed to Ca^2+^ ions in a dose-dependent way. We could additionally notice an increase of ALP activity with the incubation time. The findings similarly revealed improved differentiation of MC3T3-E1cells seeded in the presence of different concentrations of Van-MSN-CaSO~4~ or Van-CaSO~4.~

### Effect of bone cements on cytological changes {#Sec18}

The cytological examination of MC3T3-E1 osteoblasts incubated with media containing prepared leaching solutions is depicted on Fig. [3](#Fig3){ref-type="fig"}. The microscopic observation of cell morphological changes revealed that cells incubated with Van-CaSO~4~ and 5 %Van-MSN-CaSO~4~ leaching solutions were mature, clearly fusiform with increased volume. Cells in the control group without leaching solution remained polygonal and did not show obvious cell differentiation. This suggested that studied bone cements supported adhesion of osteoblastic cells on their surfaces. Altogether, the results of the in vitro biocompatibility assessment showed that the Van-MSN-CaSO~4~ implant presents no obvious cytotoxicity and could be used for clinical applications.Fig. 3Cytological analysis of morphological changes of MC3T3-E1 cells after incubation with different bone cements
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### Macroscopic observations {#Sec20}

In order to evaluate the efficacy of Van-CaSO~4~ and 5 %Van-MSN-CaSO~4~ implants in defects repair, animals were killed 3 months after bone implantation. After surgery lower extremities of femur containing defects were collected and macroscopically examined. The photographs are presented in Fig. [4](#Fig4){ref-type="fig"}. The results showed that in the MSN implant group, most of the bone defects was filled with SiO~2~ granules. No bony connection was seen in any of the 3 rabbits, but partial bone formation was observed (Fig. [4](#Fig4){ref-type="fig"}a). In Van-CaSO~4~ group, most of the defect was healed and only slight bone formation was found in sites of the defects (Fig. [4](#Fig4){ref-type="fig"}b). In the Van-CaSO~4~-MSN group, complete healing of the segmental defect was observed in all 3 rabbits. In addition remarkable new bone formation (Fig. [4](#Fig4){ref-type="fig"}c) and no residual CaSO~4~ was found in the 3 rabbits. In the control group without implant, no new bone formation was found in sites of the defects (Fig. [4](#Fig4){ref-type="fig"}d).Fig. 4Images depicting the macroscopic state of bony defects 3 months after implantation. **a** pure MSN (SiO2) implant group, **b** van-CaSO~4~ implant group, **c** van-MSN-CaSO~4~ implant group, **d** pure control group of rabbits without implant (Group 4)

### Micro-CT analysis {#Sec21}

As shown in Fig. [5](#Fig5){ref-type="fig"}, the micro-CT analysis of distal femur samples collected 3 months after implantation further confirmed the macroscopic observation results. Descriptive statistics for BV/TV, BS/BV, Tb·Th and Tb.N were determined. The results showed that (Fig. [6](#Fig6){ref-type="fig"}), the mean relative BV/TV (newly formed bone volume density) were higher at 12 weeks. The adjusted mean BV/TV were 22.92, 20.30, 28.52 and 30.65 % for control, Van-MSN, Van-MSN-CaSO~4~ and Van-CaSO~4~ implant materials, respectively. The BS/BV value was 15.77 m^−1^ for the control, 16.05 for Van-MSN, 9.69 m^−1^ for Van-MSN-CaSO~4~ and 10.32 m^−1^ for Van-CaSO~4~. The differences of BV/TV and BS/BV between Van-MSN-CaSO~4~ and Van-CaSO~4~ implant materials were not statistically significant. The trabecular thickness (Tb·Th) was smaller in the control and Van-MSN groups compared to implant groups but no statistically significant differences were observed between groups.Fig. 5Micro-CT images of femur regions containing bony defects 3 months after implantation. **a** Pure MSN (SiO2) implant group, **b** van-CaSO~4~ implant group, **c** van-MSN-CaSO~4~ implant group, **d** pure control group of rabbits without implant (Group 4)Fig. 6Descriptive statistics for BV/TV, BS/BV, Tb·Th and Tb·N measured by micro-CT

### Histological evaluation {#Sec22}

The HE staining and histological observation of decalcified bones including the defect site was performed 12 weeks after implantation. The results (Fig. [7](#Fig7){ref-type="fig"}) revealed that in the rabbits femur bone defects, distinctive lamellar bone developed at the host bone-implant boundary and within the spongy spaces of the Van-MSN-CaSO~4~ implants (Fig. [7](#Fig7){ref-type="fig"}b), as well as in the Van-CaSO~4~ implants (Fig. [7](#Fig7){ref-type="fig"}c). Small amount of new bone were similarly formed in Van-MSN implants (SiO4 alone) (Fig. [7](#Fig7){ref-type="fig"}a) while only loose connective tissue were noticed in the gap control group (Fig. [7](#Fig7){ref-type="fig"}d).Fig. 7Stained histology of femur regions containing bony defects 3 months after implantation. **a** Pure MSN (SiO2) implant group, **b** van-CaSO~4~ implant group, **c** van-MSN-CaSO~4~ implant group, **d** pure control group of rabbits without implant (Group 4)

### Pathomorphological observation of viscera {#Sec23}

In order to evaluate the toxicity of implants material, HE staining and histopathological observation of sections of main organs before and after implantation of Van-MSN-CaSO~4~ were performed. The result (Fig. [8](#Fig8){ref-type="fig"}) showed no visible significant differences of the effect of different implant groups on heart, liver, spleen, lung, kidney and other important organs. This suggested that Van-MSN-CaSO~4~ implant is biocompatible and can be used as a safe bone implant for treatment of bony defects.Fig. 8Histopathological analysis of lung, spleen, kidney, heart and liver before and 3 months after implantation of Van-MSN-CaSO~4~ implant

### Hematological index {#Sec24}

In order to further understand the cytotoxicity of artificial bone composite from biochemical point of view, we additionally determined the hematological index of studied rabbits. As shown in Table [2](#Tab2){ref-type="table"}, no statistically significant difference was observed between groups, which further confirms the biocompatibility of Van-MSN-CaSO~4.~Table 2Serum biochemical indexes of each rabbit measured before and after implantation of bone composites. G1: group1 (pure MSN (SiO2) implant group), G2: Group 2 (Van-CaSO~4~-MSN (SiO2--CaSO~4~) implant group) G3: Group 3 (CaSO~4~ implant group), G4: Group 4 (the control group without implant), N1--N12: rabbit numbersSample numberALTASTGGTLI(r-GT)UREACREAALPG1N130.126.710.211.768.568.7G1N262.620.212.38.873.246.4G1N360.515.112.310.681.749.4G2N43322.28.27.370.157.5G2N559.8259.511.574.457.6G2N645.423.57.510.365.387.1G3N728.717.78.312.566.444.3G3N841.921.28.512.283.290.5G3N965.923.26.16.977.642G4N1061.435.211.511.354.763.3G4N1141.920.710.612.598.930.7G4N1277.830.99.67.1103.831.6Before operation22.2148.16.352.863G2-2 days after operation33.556.489.358.633.4

Discussion {#Sec25}
==========

Good biocompatibility is an imperative parameter to take into account during the development of bone implant materials. In the present study, the in vitro and in vivo evaluation of Van-MSN-CaSO~4~ and Van-CaSO~4~ biocompatibility was performed in order to assess their safety and potential usefulness in bone transplantation.

The cell proliferation experiment revealed that there was no significant difference of the absorbance of MC3T3-E1 cells incubated with leaching solution originated from Van-MSN-CaSO~4~ composite when compared with Van-CaSO~4~ control group (*P* \< 0.05). The optical density (OD) values increased progressively until 5 days cultivation showing that the proliferation activity of MC3T3-E1 cells was not significantly affected. This result implies that Van-MSN-CaSO~4~ composite had no obvious toxic effects on osteoblasts as it was previously reported by Chung et al. \[[@CR18]\] who found that MSNs have no significant effect on the proliferation and differentiation of human bone marrow mesenchymal stem cells.

Osteoblasts are main functional cells of bone formation responsible for bone matrix synthesis, secretion and mineralization. As bone implant, MSNs may directly affect the osteogenesis effect of osteoblasts. ALP, as a key indicator of osteoblast maturation and differentiation \[[@CR19]\], is of great significance in evaluating the degree of differentiation of osteoblasts. In this study, we found that ALP activity increased significantly (*P* \< 0.05) over the incubation time in cultures of MC3T3 cells incubated with 5 %MSNs-CaSO~4~ leaching solution compared with the blank control group. In addition, ALP activity increased obviously with the increase of leaching solution concentration. More importantly, no significant differences were recorded between 5 % MSNs-CaSO~4~ composite leaching solution and the CaSO~4~ leaching solution control group. This further illustrates that corresponding leaching solutions did not negatively affect osteoblast proliferation but promoted cell morphological changes and differentiation. These effects are likely attributable to the Ca^2+^ solution which was previously reported to have osteoconductive effect \[[@CR19], [@CR20]\].

The effect of MSNs implants on rabbit's bone tissue fractures healing process, which is similar to that of human, have not been reported so far. The macroscopic observation and Micro-CT analysis showed that after the implantation of Van-MSN-CaSO~4~ artificial bone composite, complete healing of bony defects was observed 12 weeks after surgery compared with Van-CaSO~4~ composite and the blank control group without implant. This result shows that Van-MSN-CaSO~4~ implant did not delay the healing of bony defects or hinder bone tissue repair, which indicates its potential application as a good drug carrier implant able to concurrently accomplish bone defects filling and local drug release.

After implantation in the distal femur, CaSO~4~ can be absorbed and degraded in the body, vancomycin can enter in the metabolism of liver and kidney but whether SiO2 nanoparticles can produce certain toxicity effect to the body or not is unclear. Therefore, we further investigated the toxicity of bone implant on rabbit internal organs by histopathological observation of major organs. In addition blood biochemical index of the seemingly damaged function of liver and kidney were determined in order to understand the cytotoxicity of artificial bone composites from biochemical point of view. The result showed no significant pathological effect changes in heart, liver, spleen, lung and kidney. According to the blood biochemical test, there was no significant difference between studied groups and Van-MSN-CaSO~4~ material did not cause the body to produce apparent rejective reaction or inflammation. Therefore, the Van-MSN-CaSO~4~ bone implant can be used as the carrier of vancomycin without producing obvious toxic effect. According to previous studies, direct injections of MSNs by peritoneal or intravascular ways do not produce the same effects. In this study, the local implantation of bone materials did not cause much release of MSNs into the bloodstream and could not therefore instigate the damage of main organs.

We employed 5 %Van-MSN-CaSO~4~ rather than using a larger dose of MSNs because previous studies \[[@CR11], [@CR21]\] showed that this dose of MSNs is enough to maintain vancomycin concentration and drug release for long time. In addition this concentration is greater than the vancomycin minimal inhibitory concentrations (MIC) of *S. aureus* which is responsible for the common bacterial infection of bone. On the other hand, this proportion of MSNs does not affect the bone filling potential of CaSO~4~ material \[[@CR12]\]. One limitation of the present work could be that we did not measure the in vivo release of vancomycin, therefore it would be inaccurate to affirm that the use of MSN allows for sustained drug release. However, this issue was already studied in our previous research work where we thoroughly investigated the drug release efficiency of VAN-MSN-CaSO4 cement \[[@CR17]\].

In the process of bone formation, additionally to the osteoblasts, there are many factors that affect bone healing, such as osteoclasts and bone marrow mesenchymal stem cells \[[@CR22], [@CR23]\]. We need to further study the toxic effects of MSN materials on these cells, as well as the interaction between silica nanoparticles and organelles. We similarly need to further study safety dose of MSNs after implantation as bone filling material.

Conclusion {#Sec26}
==========

Vancomycin loaded MSNs-CaSO~4~ artificial bone material (MSNs mass fraction of 5 %) showed no obvious cytotoxic effect on MC3T3-E1 cells. The local implantation of this bone implant materials did not delay fracture healing and had no obvious damage effects on the function of main organs of rabbit. In conclusion, Van-MSN-CaSO~4~ artificial bone material has good biocompatibility and could be used for the treatment of bone defects in human since fracture healing in the rabbit is similar to that of human.
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